华润双鹤药业股份有限公司 对外信息报送和使用管理制度 (经 2025 年 12 月 2 日第十届董事会第十五次会议修订通过) 第一章 总则 第一条 为规范华润双鹤药业股份有限公司(以下简称"本公司" 或"公司")定期报告及重大事项在编制、审议和披露期间，公司对 外报送相关信息及外部使用人使用本公司信息的相关行为，依据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露 管理办法》《上市公司监管指引第 5 号——上市公司内幕信息知情人 登记管理制度》《上海证券交易所股票上市规则》等有关法律、法规、 规范性文件及公司《章程》《信息披露事务管理制度》等有关规定， 制定本制度。 公司证券事务管理部门负责协助董事会秘书做好信息对外报送 的日常管理工作。 公司各归口单位或相关人员应按照本制度规定履行信息对外报 送程序。 第二章 对外信息报送的管理及流程 第五条 公司董事和高级管理人员及其他相关涉密人员在定期 报告编制、公司重大事项筹划期间，负有保密义务。定期报告、临时 公告公布前，不得以任何形式、任何途径向外界或特定人员泄露定期 报告、临时公告的内容，包括但不限于业绩座谈会、分析师会议、接 受投资者调研座 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－104 华润双鹤药业股份有限公司 关于取消监事会、修订公司《章程》及全面修订 基本管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2025 年 12 月 2 日公司第十届董事会第十五次会议、第十届监事 会第十二次会议分别审议通过《关于修订公司<章程>的议案》《关于 全面修订公司基本管理制度的议案》及《关于取消监事会的议案》， 具体情况如下： 一、取消监事会 为落实《中华人民共和国公司法》(以下简称《公司法》)、中国 证监会出台的配套规章及规范性文件要求，公司不再设置监事会，免 去监事会主席及监事职务，原监事会的职权由董事会审计与风险管理 委员会行使，《监事会议事规则》相应废止。在公司股东会审议通过 取消监事会前，第十届监事会及现任监事仍将严格履行监督职责，维 护公司和全体股东的利益。 二、修订公司《章程》 为进一步完善公司治理架构，促进规范运作，公司根据《公司法》 《关于新<公司法>配套制度规则实施相关过渡期安排》《上市公司章 程指引》等相关 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－103 华润双鹤药业股份有限公司 关于变更注册资本的公告 上述变更注册资本事项需提交股东会审议批准。 特此公告。 华润双鹤药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2025 年 12 月 2 日公司第十届董事会第十五次会议审议通过《关 于变更注册资本的议案》，具体情况如下： 鉴于公司 2021 年限制性股票激励计划部分激励对象不符合激励 条件，公司拟回购注销部分激励对象已获授但尚未解除限售的限制性 股票 17.4998 万股，导致公司股份总数、注册资本发生变化，公司股 份总数变更为 103,858.2511 万股，注册资本减少至 103,858.2511 万元。 董 事 会 2025 年 12 月 4 日 1 ...

第十届监事会第十二次会议 2025 年 12 月 2 日 华润双鹤药业股份有限公司 第十届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、监事会会议召开情况 公司第十届监事会第十二次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 11 月 28 日以邮件 方式向全体监事发出，会议于 2025 年 12 月 2 日以现场及通讯方式召 开。出席会议的监事应到 5 名，亲自出席会议的监事 5 名。会议由监 事会主席刘建国先生主持。公司董事会秘书刘驹先生列席会议。 二、监事会会议审议情况 1、关于公司及经理层成员 2024 年业绩合同评价结果及薪酬分配 的议案 结合公司 2024 年的业绩成绩及经理层成员的履职情况，同意公 司及经理层成员 2024 年业绩合同评价结果以及薪酬分配方案。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－102 第十届监事会第十二次会议 2025 年 12 月 2 日 监事会及现任监事履行职责至股东会审议通过取消 ...

第十届董事会第十五次会议 2025 年 12 月 2 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－101 华润双鹤药业股份有限公司 第十届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、董事会会议召开情况 公司第十届董事会第十五次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 11 月 28 日以邮件方 式向全体董事发出，会议于 2025 年 12 月 2 日以现场及通讯方式召开。 出席会议的董事应到 11 名，亲自出席会议的董事 10 名。董事长陆文 超先生因工作原因委托董事赵骞先生出席会议，并授权对本次会议通 知中所列议题代行同意的表决权。会议由半数以上董事共同推选赵骞 先生主持。公司监事列席会议。公司董事会秘书刘驹先生列席会议。 二、董事会会议审议情况 1、关于变更注册资本的议案 鉴于公司回购注销部分激励对象已获授但尚未解除限售的限制 性股票 17.4998 万股，导致公司股份总数、注册资本发生变化，同意 公司注册资本减 ...

Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]

Policy Trends - In 2024, the total number of medical consultations in China reached 10.15 billion, an increase of 600 million from the previous year, with a life expectancy of 79.0 years and a maternal mortality rate of 14.3 per 100,000 [1] - The total number of medical institutions in China reached 1,093,551 by the end of 2024, an increase of 22,766 from the previous year, including 38,710 hospitals [1] - The number of health technicians in China reached 13.02 million, an increase of 531,000 (4.3%) from the previous year, with 9.37 million working in hospitals [1] Healthcare Costs - The average hospitalization cost in hospitals for 2024 was 9,870 yuan, a decrease of 4.3% from the previous year, while the average outpatient cost was 361 yuan, down 0.2% [2] - The total healthcare expenditure in China for 2024 was approximately 9,089.55 billion yuan, with government spending accounting for 24.9%, social spending for 47.6%, and personal spending for 27.5% [2] - The per capita healthcare expenditure was 6,454.4 yuan, with total healthcare expenditure constituting 6.7% of GDP [2] Pharmaceutical Developments - The National Medical Insurance Administration launched a drug price registration and inquiry service, allowing pharmaceutical companies to self-declare drug prices for public access [3] - Renfu Pharmaceutical announced the withdrawal of its application for the registration of a recombinant plasmid-hepatocyte growth factor injection, which had a cumulative R&D investment of approximately 160 million yuan [4] - Hengrui Medicine received acceptance for its application for the marketing authorization of remimazolam tosylate for sedation during mechanical ventilation in intensive care [4] Investment Activities - China Resources Sanjiu established a biopharmaceutical fund in Hohhot with a total investment of 500 million yuan, focusing on private equity investments and asset management [5] - Zhaoli Pharmaceutical plans to raise up to 1.556 billion yuan through convertible bonds for the development of an intelligent traditional Chinese medicine health factory and other projects [6] Global Health Issues - The World Health Organization reported that reductions in international aid are impacting global HIV prevention efforts, with significant challenges ahead for AIDS response programs [7] Regulatory Actions - Jiangsu Wuzhong received a delisting notice from the Shanghai Stock Exchange due to major violations, including concealing changes in actual control and severe financial fraud [8] - The company is set to enter a delisting transition period on December 9, 2025, with the last trading day expected to be December 29 [8]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Pioglitazone Hydrochloride Dispersible Tablets, which is expected to enhance market competitiveness and sales potential in the future [1][2]. Group 1: Drug Approval and Development - The company’s subsidiary, Shuanghe Tianan Pharmaceutical, received the approval notice for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1]. - The consistency evaluation for this drug began in 2017, with the application submitted in December 2024 and approval received in November 2025 [2]. - The total R&D investment for this drug's consistency evaluation has reached RMB 8.8227 million (unaudited) [2]. Group 2: Market Situation of Similar Drugs - Pioglitazone tablets, developed by Takeda Pharmaceutical, were approved in the U.S. in July 1999 and in China in 2004, but have since been withdrawn from the market [3]. - The global sales of Pioglitazone tablets are projected to be USD 254 million in 2024, with "ACTOS" contributing USD 41.6958 million [3]. - In China, the total sales of Pioglitazone tablets in the medical and retail markets are estimated at RMB 349 million in 2024, with Shuanghe Tianan holding a market share of 10.46% [3].

Core Viewpoint - The article highlights the transformation of China Resources Double Crane into a leading pharmaceutical group through smart manufacturing, strategic acquisitions, and international expansion, particularly in the medical infusion sector and innovative drug development [1][3][8]. Group 1: Smart Manufacturing - Henan Double Crane Huali Pharmaceutical Co., a subsidiary of China Resources Double Crane, has achieved a production speed of nearly 800 bottles (bags) per minute, positioning itself as a benchmark in the medical infusion industry [1][4]. - The company has implemented a fully automated production line, achieving "unmanned" operations throughout the entire process, which has led to a 15% to 20% increase in production efficiency and a 10% to 15% rise in daily output [4][5]. - The intelligent warehouse, with a capacity of approximately 50 million bottles (bags), is the largest modern smart warehouse in Henan Province, further enhancing operational efficiency [4]. Group 2: Strategic Acquisitions - China Resources Double Crane has a strong track record in acquisitions, having acquired companies like Shenzhou Biological, Tianan Pharmaceutical, and Huaren Zizhu to diversify its product portfolio and expand beyond infusion products [6]. - The recent acquisition of Zhongshu Pharmaceutical allows the company to enter the psychotropic drug market, with expectations for significant revenue growth from its core product, which is anticipated to reach a billion-level market size by 2025 [6][7]. - The company is focusing on acquiring leading firms in high-growth areas such as mental health, ophthalmology, and pediatrics, while also enhancing its biomanufacturing capabilities [7]. Group 3: International Expansion - China Resources Double Crane aims to shift from raw material exports to finished product exports, emphasizing product differentiation as a key strategy for international markets [8]. - The company plans to establish an international business department to coordinate its global operations and enhance its competitive edge in the international pharmaceutical market [8]. - Future international strategies include leveraging the Hainan Free Trade Port's advantages to create a global health production base and pursuing overseas acquisitions, particularly in Europe and the U.S. [8].

Core Viewpoint - The company is advancing its smart manufacturing capabilities, enhancing production efficiency and competitiveness through automation and digitalization, while also focusing on innovation and international expansion in the pharmaceutical sector [2][3][4]. Group 1: Smart Manufacturing and Automation - The new facility emphasizes automation, digitalization, and intelligent design, incorporating advanced equipment such as AI inspection machines and integrated filling machines, achieving industry-leading smart manufacturing levels [3]. - Production efficiency has increased by 15% to 20%, with daily output rising by 15%, significantly enhancing competitiveness [3]. - Since relocating in 2021, overall production capacity has surged by 346% without increasing labor costs, resulting in a 310% rise in per capita labor productivity [3]. Group 2: Digital Transformation - The company has accelerated its digital transformation, achieving an 85% digital coverage rate in key business areas and receiving recognition as an "Excellence Level Smart Factory" [4]. - The digital transformation supports operational excellence and innovation, aligning with the company's strategic goals [4]. Group 3: Product and Market Expansion - The company is committed to low-cost, large-scale, multi-product, innovative, and high-quality strategies, focusing on developing products that better serve clinical needs [6]. - The acquisition of global commercialization rights for a new diabetes treatment marks a significant advancement in addressing unmet medical needs in the diabetes foot ulcer market [6]. Group 4: Innovation and R&D Strategy - The company aims to balance generic and innovative drug development, utilizing a "License-out" strategy to manage R&D costs and enhance quality while expanding international presence [7]. - Mergers and acquisitions are pivotal for expanding the product portfolio and driving innovation, with a focus on leading companies in niche markets and biomanufacturing [8]. Group 5: Synthetic Biology and Future Growth - The company has established a "raw material and formulation integration" strategy, acquiring biopharmaceutical firms to enhance profitability through synthetic biology technologies [9]. - The synthetic biology research institute has been set up to drive innovation, with several products already in the pilot testing phase, focusing on raw materials and specialty formulations [10]. Group 6: Strategic Goals and Internationalization - The company aims to become the leading brand in prescription drugs in China, with plans to enhance brand influence and expand its product pipeline through strategic acquisitions [11]. - Internationalization is viewed as a key pathway for achieving strategic goals, transitioning from raw material exports to finished product exports to enhance competitiveness in the global market [11].